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In situ identification and G 4‑P PI‑ His 
‑Ma l‑d end rim er‑induced reduction 
of early‑stage amyloid aggregates 
in Alzheimer’s disease transgenic 
mice using synchrotron‑based 
infrared imaging
Núria Benseny‑Cases1*, Elena Álvarez‑Marimon2, Ester Aso3, Margarita Carmona3, 
Oxana Klementieva4, Dietmar Appelhans5, Isidre Ferrer3 & Josep Cladera2*
Amyloid plaques composed of Aβ amyloid peptides and neurofibrillary tangles are a pathological 
hallmark of Alzheimer Disease. In situ identification of early‑stage amyloid aggregates in Alzheimer’s 
disease is relevant for their importance as potential targets for effective drugs. Synchrotron‑based 
infrared imaging is here used to identify early‑stage oligomeric/granular aggregated amyloid species 
in situ in the brain of APP/PS1 transgenic mice for the first time. Also, APP/PS1 mice show fibrillary 
aggregates at 6 and 12 months. A significant decreased burden of early‑stage aggregates and fibrillary 
aggregates is obtained following treatment with poly(propylene imine) dendrimers with histidine‑
maltose shell (a neurodegenerative protector) in 6‑month‑old APP/PS1 mice, thus demonstrating 
their putative therapeutic properties of in AD models. Identification, localization, and characterization 
using infrared imaging of these non‑fibrillary species in the cerebral cortex at early stages of AD 
progression in transgenic mice point to their relevance as putative pharmacological targets. No less 
important, early detection of these structures may be useful in the search for markers for non‑invasive 
diagnostic techniques.
Alzheimer’s Disease (AD) is characterized by the presence of senile plaques mainly composed of Aβ peptides 
and neurofibrillary tangles resulting from aberrant intraneuronal deposition of phosphorylated tau species. 
However, recent experimental evidence supports the idea that amyloid fibrils are not necessarily toxic whereas 
toxic species relevant to the onset and progression of the disease are found among a diverse population of on- and 
off-pathway non-fibrillary intermediates. Although some of these non-fibrillary amyloids and their toxicity have 
been described in vitro, and different oligomeric species have been isolated from affected brain  homogenates1–3, 
the challenge remains regarding their identification in vivo and the time at which they form, presumably long 
before the appearance of neurological deficits. Whereas powerful imaging techniques such as MRI and PET 
are being used to detect the presence of fibrillary amyloids, and in some cases, oligomeric species have been 
 targeted4–8, the detection of earlier non-fibrillary aggregates and their structural characterization, which would 
facilitate the design of effective drugs, remain elusive.
Infrared microscopy (µ-FTIR) has been used in the last decade for the in situ study of amyloid  deposits9–13. 
In the present work, we have used synchrotron-based µ-FTIR to describe the early formation of non-fibrillar 
amyloid aggregates in brains of APP/PS1 transgenic  mice14–17 at 3, 6, and 12 months and to evaluate the effect 
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of poly(propylene imine) dendrimers with histidine-maltose shell (G4-His-Mal dendrimers)18 as anti-neuro-
degenerative agents in mice.
Results and discussion
Fourier Transform Infrared (FTIR) spectra were measured in the cerebral cortex of 3-, 6-, and 12-month-old 
APP/PS1 transgenic mice, age-matched wild type (WT) mice and 6-month-old APP/PS1 mice treated with 
G4-His-Mal dendrimers. Supplementary Figs. S1 and S2 provide two examples of the regions measured in the 
animal’s cortex and how the detected amyloid deposits co-localize with a positive anti-amyloid antibody label 
in a contiguous slide of the tissue.
The scores graph and the corresponding loadings of the Principal Component Analysis (PCA) of the whole 
set of data is shown in supplementary Fig. S3. In order to facilitate data visualization and interpretation the score 
plot of the whole data set has been broken down and the resulting graphs are shown in Figs. 1 and 5 in this sec-
tion. Representing the principal component 1(PC1) versus the principal component 3 (PC3) has given a score 
graph in which two set of outliers (points corresponding to spectra outside the region in which the WT spectra 
appear) are more clearly resolved than in the PC1 vs. PC2 plot (data not shown). According to the loadings graph, 
the outliers on the PC1 axis differ from the WT spectra in a main feature centred at 1628  cm−1, characteristic 
of peptide/protein fibrillary aggregation. The PC3 loadings show two features centred at 1620 and 1695  cm−1, 
characteristic of non-fibrillary/amorphous/granular (non-fibrillar β-sheet)  structures19–21.
Oligomeric/granular (O/G) and fibrillary amyloid aggregates in APP/PS1 mice at 3, 6 and 
12 months of age. Figure 1 shows the score plot of the PCA of the amide I region for 3-, 6-, and 12-month-
old APP/PS1 represented together with WT data. Since, according to the loadings graph (supplementary Fig. S1) 
the typical wavenumber for intermolecular fibrillary β-sheet is the dominant feature of PC1, PC1 can be used 
to classify the spectra as a function of fibrillary amyloid content. In the same way, being PC3 indicative of non-
fibrillary β-sheet structures, PC3 values can be used to classify the spectra depending on the presence of oligo-
meric/granullar β-sheet content. We have done so by segmenting the data points outside the area corresponding 
to the WT points in two different groups: outliers in the direction of the negative PC1 (segmented in orange in 
Fig. 1); and outliers in the direction of the positive PC3 (segmented in blue in Fig. 1).
In order to further characterize the structural differences between the different groups of outliers the mean 
of the FTIR spectrum of all data points in each segment in Fig. 1 was calculated and compared with the average 
spectra of the WT points. The derivative spectra corresponding to the PC1 segments (a–d), depicted in orange 
in Fig. 1 (bottom panels) show a β-sheet fibrillary aggregation band at 1630  cm−1 (consistent with the 1628  cm−1 
Figure 1.  Principal component analysis (PCA) score plots of infrared spectra from brain samples of WT mice 
and APP/PS1 mice 3 months (a), 6 months (b) and 12 months (c) old. WT data is shown in red and APP data 
in grey. The loadings corresponding to the PCA scores are shown in Fig. S1 together with the PCA scores of the 
whole set of data using in this study (APP/PS1 + treated with G4-His-Mal dendrimer). The bottom row shows 
the normalized second derivative mean spectra of the amide I region calculated from the individual spectra in 
each outlier segment (a–f) on the PCA scores, for APP/PS1 mice 3 months (d), 6 months (e) and 12 months (f) 
old. Colour code: each average derivative spectrum has the same colour as the corresponding coloured segment 
in which the outlier spectra appear in the top row. In orange, segments (a–d) in the direction of the negative 
PC1 axis; in blue, segments (e,f) in the direction of the positive PC3 component; in red, the average spectrum of 
the WT data points. Unscrambler X software (CAMO, Oslo, Norway) was used to perform PCA and Origin 9.1 
and Microsoft power point 2016 software were used for graphical representation.
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feature detected in the PC1 loadings in Figure S3), which intensity increases as the PC1 value becomes more 
negative, together with a shift of the minimum at 1655  cm−1 towards 1659  cm−1. Fibrillary structures can therefore 
be characterized by the presence of these two features in the second derivative spectra: a band at 1630  cm−1 and 
an increase in intensity at 1659  cm−1. The derivative spectra corresponding to the PC3 segments (e,f), depicted 
in blue, show a band at 1625  cm−1 (this band represents a shift with respect to the 1630  cm−1 band of the fibrillary 
structures and is compatible with the shifted 1620  cm−1 feature in the PC3 loadings in Figure S3) and a band 
centred at 1695  cm−1 (the same wavelength observed in the PC3 loadings), both characteristic of a non-fibrillar 
β-sheet structure. Comparison of these spectral features with the FTIR (second derivative) spectra of known 
aggregated species generated in vitro, shown in Fig. 2, permits to clearly identify the aggregated species detected 
in APP/PS1 mice brains as oligomeric/granular aggregates (O/G, β structures of non-fibrillary nature, with a 
high frequency component, characteristic of non-fibrillary β sheets) and fibrillary aggregates. The biophysical 
analysis of these in vitro aggregates is displayed in Fig. S4, showing the morphology of the fibrils and the non-
fibrillary aggregates together with the ThT fluorescence kinetics, which is clearly more intense in the presence 
of fibrils. Such infrared spectral features for non-fibrillary and fibrillary amyloid structures have also been 
reported in previous in vitro  studies19–21. It is worth emphasizing that the spectra depicted in Fig. 2 correspond 
to the amyloid peptide aggregated under incubation conditions that lead to the formation of either fibrillary 
aggregates (neutral pH) or amorphous/granular aggregates (pH 5.5). The spectral features of the amorphous 
aggregated species at pH 5.5 turn out to be very similar to those reported by Sarroukh et al.20 for oligomeric Aβ 
(both Aβ(1–40) and Aβ(1–42)). Our own data together with previous studies show that the spectral features of 
fibrils and oligomeric/amorphous/granular aggregates are very similar for both Aβ(1–40) and Aβ(1–42). This 
means that infrared spectra cannot be used as a tool to distinguish between oligomers and amorphous aggregates 
nor to differentiate the aggregates formed by Aβ(1–40) from the ones formed by Aβ(1–42). However, it clearly 
differentiates fibrillary from non-fibrillary aggregates.
The correspondence between the distinct spectroscopic features and the fibrillary/non-fibrillary structures 
is proven by the TEM images shown in Fig. S4. In relation to the aggregated structures at pH 5.5, although the 
TEM images do not permit to deduce any structural detail other than the amorphous/granular aspect, it is clear 
that the aggregates are non-fibrillary, and besides the large amorphous clumps individual round dots, compatible 
with big oligomeric structures are normally distinguished. In our previous  studies19 with Aβ(1–40) we showed 
that granular (amorphous) aggregates formed at pH 5.5 could be transformed into fibrils by increasing the pH 
to 7.4 and that this transformation followed the typical sigmoidal kinetics. For this reason, we speculated with 
the possibility that these granular aggregates could be a source of oligomeric forms given the right conditions 
(i.e. an increase of the pH). For all these reasons we refer to the amorphous aggregates of granular aspect with 
the same spectroscopic characteristics as oligomeric structures as O/G aggregates. Aβ(1–40) O/G aggregates 
are known to be toxic to neuroblastoma cells in  culture19. Toxicity assays with Aβ(1–42) have shown that this 
peptide incubated at pH 5.5 is as well toxic (data not shown).
It can be concluded from Fig. 1 that these two types of aggregated structures (fibrillary and O/G non-fibrillary 
aggregates) start forming in APP/PS1 mice brains at 3 months of age, both types do clearly increase at 6 months 
and at 12 months a further increase of the fibrillary structures and a decrease of the O/G aggregates is detected.
These results, showing the evolution of both types of amyloid aggregates with mice age, can be formulated 
as well in terms of the differences in the values of the spectroscopic ratios reported in Fig. 3. For all the ratios, 
the main band of the WT spectra at 1655  cm−1 was taken as the reference band against which the intensity of 
the characteristic bands of the different aggregated species was measured. The ratios  A1630/A1655 and  A1659/A1655 
were taken as the spectroscopic signature of fibrillary aggregates, and the ratios  A1695/A1655 and  A1625/A1655 as the 
spectroscopic signature of the O/G aggregates.
Figure 2.  Average second derivative spectra of the amide I region of (a) Aβ(1–40) and (b) Aβ(1–42) amyloid 
aggregates generated in vitro: fibrils (orange and blue respectively) generated at pH 7.4 and Aβ granular non-
fibrillary aggregates (red and green respectively) generated at pH 5.5. The absorbance spectra were normalized 
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Experimental points with values of the ratios at  A1630/A1655 and  A1659/A1655 (fibrillary structures) higher than 
the values calculated for the WT are clearly more abundant at 6 and 12 months and their abundance increase 
with age (Fig. 3a,b).
Figure 3c,d, shows that the abundance of O/G non-fibrillary structures is significantly increased in APP/PS1 
compared to WT (experimental points with a value of the ratios  A1695/A1655 and  A1625/A1655 higher than the values 
calculated for the wild type), and they are more abundant at 3 and 6 months than at 12 months.
Since µ-FTIR makes possible the representation of the spatial distribution of the detected chemical species, 
the different types of amyloid aggregates (fibrillary, non-fibrillary O/G) can be visualized in the form of infrared 
maps using the corresponding absorbance ratios, as illustrated in Fig. 4. In the figure, the infrared maps are shown 
together with the corresponding image obtained in the visible region of a contiguous brain slide labelled with a 
fluorescent amyloid antibody. A more detailed illustration of the co-localization of the infrared regions in which 
the infrared spectra have been measured, with the anti-amyloid positively labelled plaques using a contiguous 
tissue slide is given in supplementary Figs. S1 and S2.
Effect of G4‑His‑Mal dendrimers on amyloid aggregation in APP/PS1 mice brains. G4-His-Mal 
dendrimers are biocompatible globular branched polymers containing maltose and histidine on their surface 
with potential anti-neurodegenerative properties. Using µ-FTIR we have analysed the effect of G4-His-Mal den-
drimers on the aggregated species in the brains of 6-month-old APP/PS1 mice. For these experiments 6-month-
old APP/PS1 mice were chosen as they showed significant memory impairment as revealed in the V-maze17. The 
µ-FTIR results clearly show (Fig. 5) that the treatment of APP/PS1 intranasally with a dose of 5 µg per day of 
G4-His-Mal dendrimers results in reduced formation of early (O/G) amyloid aggregates and that the amount of 
fibrillary β-sheet is decreased in number and intensity compared to APP/PS1 mice of the same age.
Recently, our group has proven the neuroprotective potential of G4-His-Mal dendrimers, demonstrating 
that its intranasal administration protects APP/PS1 mice from synapse and memory  impairment18. This work 
by Aso et al. showed that G4-His-Mal dendrimers have a significantly improved biocompatibility and the abil-
ity to effectively cross the blood brain barrier. Other previously assayed glycodendrimers did not show the 
capacity to prevent the neurodegenerative effects in transgenic mice. The work by Aso et al. showed as well that 
G4-His-Mal dendrimers have the capacity to interact, in vitro, with the amyloid peptide, interfering with the 
Figure 3.  Box plot graphics depicting the absorbance ratio values corresponding to the two different types 
of aggregated species identified at 3, 6, and 12 months in APP/PS1 and WT mice. Amyloid fibrils (a, b: the 
ratios  A1630/A1655 and  A1659/A1655 are the two spectral features of fibrillary structures as explained in “Results 
and discussion” section) and Oligomeric/granular aggregates (c, d: the ratios  A1695/A1655 and  A1625/A1655 are the 
two spectral features of non-fibrillary aggregated structures as explained in “Results and discussion” section). 
Ratios are calculated from the second derivative spectra of the outliers in each segment (a–f) in the PCA shown 
in Fig. 1. Boxplot shows the median (center line), interquartile range (IQR) (box); whiskers represent the most 
extreme data located no more than 1.5xIQR from the edge of the box, and outliers are the points outside this 
range. T-test is used for comparison with WT (red*), 12 month mice (*), and between 3 and 6 month mice (**) 
at p < 0.002. Origin 9.1 and Microsoft power point 2016 software were used for graphical representation.
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nucleation-dependent polymerization process and resulting in a slowing down of the whole reaction and a clear 
decrease of the amount of ThT-positive fibrils formed at the end of the process. The fibrils which still form show, 
moreover, a different morphology and appear under the electron microscope as ‘clamped fibrils’, a morphology 
that has been observed as well previously as a result of the interaction of other (non-maltose) glycodendrimers 
with the amyloid  peptide22,23.
Although in the same work Aso et al.18, using OC antibodies seemed to observe an increase in Aβ  fibrils18 the 
results from the present paper clearly show that the formation of fibrils is reduced. These results could be compat-
ible with the before-mentioned in vitro observation that the interaction of G4-His-Mal dendrimers reduces the 
formation of ThT-positive amyloid fibrils. However, at this point, we do not have enough data to presume any 
mechanistic explanation of the molecular interactions by which the action of G4-His-Mal dendrimers result in 
such a reduced fibril and O/G aggregates formation in the mice affected brains. Besides a direct interaction with 
the amyloid peptides (or peptide aggregate deposits) one must consider the possibility of indirect effects such as 
the ones that could be derived from potential ability of the histidine-decorated dendrimer shells acting as metal 
cation chelators and modulating in this way the influence that copper ions may have for amyloid aggregation 
and toxicity and the relevance of tissue oxidative processes for the onset and development of the pathology. New 
research following these avenues, as for example the investigation of the effect of G4-His-Mal dendrimers on 
the levels of cationic metals in the treated mice brains using synchrotron X-ray fluorescence techniques will be 
needed. This type of studies may yield results that could permit to gain insight on the molecular mechanisms 
Figure 4.  Representative infrared and visible maps of a fibrillary plaque (left panels) and an Oligomeric/
Granullar plaque (right panels). (Top row) Images in the visible region of the plaque labeled with an antiamyloid 
antibody in a contiguous brain slide; (Midle row) absorbance ratios corresponding to fibrillary β-sheet amyloid 
aggregation; (Bottom row) absorbance ratios corresponding to antiparallel β-sheet aggregation distribution. 
Ratios were calculated from the second derivative spectra. Scale bar = 10 μm. Opus 7.5 (Bruker) software was 
used for the maps representation.
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that could explain the reduction in fibrillization and O/G oligomer formation described in the present work and 
the neuroprotective effects.
In a previous paper, Klementieva et al.24 described the formation of pre-plaque non-fibrillary amyloid struc-
tures in Tg19959 transgenic mice. In the present study, we have confirmed the presence of non-fibrillary struc-
tures in APP/PS1 mice and have characterized the structure of these aggregates in more detail. Moreover, we 
show that treatment with G4-His-Mal dendrimers reduces fibrillary aggregation and, importantly, the formation 
of non-fibrillary (O/G) aggregates.
Conclusion
Altogether, our results show that non-fibrillary aggregated species (O/G) are abundant in the cerebral cortex 
at an early stage of disease progression in APP/PS1 transgenic mice. Moreover, the levels of such non-fibrillary 
structures (and the aggregation level in general) are severely reduced in APP/PS1 mice treated with the spherical 
dendritic scaffold of H-bond- and ionic interaction-active G4-His-Mal dendrimers.
These non-fibrillary aggregated forms have previously been described in a number of in vitro studies includ-
ing the formation of synthetic Aβ(1–40) amorphous/granular toxic aggregates at pH 5.5 and in the presence of 
metal ions and of unordered structures in amyloid aggregates, the occurrence of oligomeric species contain-
ing non-fibrillary β structures, and the purification of different types of oligomers such as Aβ*56 from brain 
 homogenates19–21,25–27.
Identification, localization, and further characterization of these non-fibrillary species in the cerebral cortex 
at early stages of AD progression in transgenic mice point to their relevance as putative pharmacological targets. 
Successful decreased deposition of these species following treatment with G4-His-Mal dendrimers buoys further 
Figure 5.  (a) Scores of the Principal component analysis (PCA) using the second derivative of the amide I 
region of infrared spectra showing data from WT mice, APP/PS1 mice 6 months old and APP/PS1 6 months 
old treated with G4-His-Mal dendrimers. WT data is shown in red, APP/PS1 data in grey and APP/PS1 treated 
with G4-His-Mal dendrimers in blue. The loadings corresponding to the PCA scores corresponding to the 
mice treated with G4-His-Mal- dendrimers are depicted in Fig. S1 together with the PCA scores of the whole 
set of data used in this study; (b) normalized mean second derivative of the amide I region calculated from the 
individual spectra of the data points within the colour circle/rectangle in the outlier regions of the PCA scores. 
The bottom row shows the box plot graphics depicting the absorbance ratio values corresponding to the two 
different types of aggregated species calculated from the second derivative spectra of the data points within 
the colour circle/rectangle in the outlier regions of the PCA scores. Fibrillary aggregates are shown in (c) and 
oligomeric/granular aggregates in (d). Boxplot shows the median (center line), interquartile range (IQR) (box); 
whiskers represent the most extreme data located no more than 1.5xIQR from the edge of the box, and outliers 
are the points outside this range. T-test is used for comparison with WT (red*) and 6 months mice (*black) at 
p < 0.002. Colour code: each set of point in the box plots has the same colour as the circle with which the data 
points from which the ratios have been marked in the scores plot. Unscrambler X software (CAMO, Oslo, 
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research in this line. No less important, early detection of these structures may be useful in the search for markers 
for non-invasive diagnostic techniques.
Materials and methods
Animals. All animal procedures were conducted according to the European Union directive 2010/63/EU and 
approved by the ethics committee of the University of Barcelona. APP/PS1 transgenic mice express a chimeric 
mouse/human APP (Mo/HuAPP695swe: APP Swedish mutation) and a mutant human presenilin 1 (PS1-dE9); 
the included Swedish mutation (K595N/M596L) elevates the amount of β-amyloid, and the mutant PS1 allele 
accelerates the β-amyloid deposition rate as well as exacerbating pathological  severity17. APP/PS1 transgenic 
mice and wild-type (WT) littermates were used for the experiments. The human mutated forms APPswe and 
PS1dE9 were developed by co-injection of the two transgene constructs [Mo/Hu "humanized" chimeric APP695 
harbouring the Swedish (K594M/N595L) mutation and exon-9-deleted PS1] delivered by mouse prion pro-
moter into pronuclei with a single genomic insertion site, resulting in the two transgenes being transmitted as 
a single Mendelian locus. To homogenize the genetic background of mice, the first heterozygous generation 
was bred for at least 15 generations on a C57BL6J background, with selection for the double mutant transgenes 
at each generation. Afterward, heterozygote/WT mating produced WT and double-transgenic APP/PS1 litter-
mates for subsequent experiments.
To screen for the presence of the transgenes, genomic DNA was isolated from 1 cm tail clips and genotyped 
with the polymerase chain reaction (PCR) technique using the PCR conditions proposed by Jackson Laboratory. 
For the experiment, animals were maintained under standard animal housing conditions in a 12-h dark–light 
cycle with free access to food and water. The experiments were carried out in compliance with the ARRIVE 
guidelines.
Preparation of mice brain tissue for synchrotron FTIR mapping. WT and APP/PS1 mice aged 3, 
6, and 12 months (n = 3–4 per time point) were deeply anaesthetized by intraperitoneal injection (0.2 mL/10 g 
body weight) with a mixture of ketamine (100 mg/kg) and xylazine (20 mg/kg) prior to intracardiac perfusion 
of 4% paraformaldehyde delivered with a peristaltic pump at 19 mL/min for 5 min. Brains were removed and 
post-fixed overnight at 4 °C in the same fixative solution. Tissue samples were embedded in paraffin, and coronal 
sections 8 μm thick were cut on a microtome and mounted on  CaF2 windows (Crystran, U.K).
Synthesis of poly(propylene imine) maltose‑histidine (G4His‑Mal) dendrimers. Synthesis of 
G4HisMal was performed as in Aso et al.18. Briefly, poly(propylene imine) dendrimers of the 4th generation were 
modified with His (G4-His), and then G4-His was modified with maltose (G4-His-Mal). The whole conversion 
process was carried out in argon protection atmosphere. The structure of G4-His-Mal dendrimers is depicted in 
supplementary Fig. S5.
G4‑His‑Mal dendrimers treatment. The experiments were carried out on male APP/PS1 and wild-type 
mice. At the age of 3 months, animals were randomly divided as follows: 7 transgenic and 6 WT mice received 
intranasally a dose of 5 μg per day of G4-His-Mal dendrimer (5 μL of 1 mg/mL solution); 5 transgenic and 6 WT 
mice received the same volume of PBS (5 μL) until animals reached the age of 6 months.
Preparation of Aβ(1–40) aggregates in vitro. Aβ(1–40) peptide [DAEFRHDSGYEVHHQKLVF-
FAEDVGSNKGAIIGLMVGGVV] was purchased from JPT (Germany) with  Cl− as a counterion. The peptide 
(500 μM) was dissolved in 10 mM PBS buffer with 0.04%  NH3 at pH 12 (pH adjusted using NaOH) and soni-
cated for 30 s to ensure that it was in monomeric condition as described in Benseny-Cases et al.19. The stock 
solutions were kept at − 80 °C until use. The stock solutions were diluted at 200 μM in PBS buffer and the pH was 
adjusted to pH 7.4 (to trigger amyloid fibril formation) and to pH 5.5 (to trigger amyloid amorphous aggregates 
formation) using HCl and were then incubated overnight and mixed at 200 rpm and 37 °C. After incubation, 
in vitro aggregates were dried directly on  CaF2 windows.
SR‑FTIR microspectroscopy and data acquisition. SR-μFTIR was performed at the MIRAS beamline 
at ALBA synchrotron (Catalonia, Spain), using a Hyperion 3000 Microscope that was equipped with a 36× mag-
nification objective coupled to a Vertex 70 spectrometer (Bruker). The measuring range was 650–4000   cm−1 
and the spectrum collection was carried out in transmission mode at 4  cm−1 resolution, 10 μm × 10 μm aperture 
dimensions, and co-added from 64 to 128 scans. Zero filling was performed with fast Fourier transform (FFT) so 
that in the final spectra there was one point every 2  cm−1. Background spectra were collected from a clean area 
of the  CaF2 window every 10 min. Mercury–cadmium–telluride (MCT) detector was used and the microscope 
and spectrometer were continuously purged with nitrogen gas.
Fourier transform infrared (FTIR) spectrum analysis. Fourier transform infrared (FTIR) spec-
tra from the different maps, and the independent spectra of amyloid aggregates were analyzed with Opus 7.5 
(Bruker) software. Atmospheric compensation was applied to the spectra to remove water vapour and  CO2 con-
tributions. The spectra exhibiting a low signal-to-noise ratio were eliminated and concave rubberband baseline 
corrected (RBC) in the range of 3100–1400  cm−1 using 64 baseline points and 5 iterations. An example of one 
set of spectra after and before rubberband corrections is displayed in supplementary Figure S6. Unscrambler X 
software (CAMO, Oslo, Norway) was used to perform PCA in the data set as in Benseny-Cases et al.10. Briefly, 
PCA analysis was applied on the second derivative of the spectra calculated using a Savitsky-Golay algorithm 
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with a thirteen point filter and a polynomial order of 3. Unit vector normalization was applied after secondary 
derivation for PCA analysis.
Principal components (PCs) were calculated using the Unscrambler X software (CAMO) Software was 
also used for the normalized average spectra and the second derivative spectrum calculation. Ratios were cal-
culated over the following peaks representing different protein secondary structures in the Amide I region: 
1695  cm−1/1655  cm−1 associated to 1625  cm−1/1655  cm−1 for the non-fibrillary (oligomeric, granular aggre-
gates) β-sheet structures (noted as  A1695/A1655 and  A1625/A1655), 1630  cm−1/1655  cm−1 (noted as  A1630/A1655) and 
1659  cm−1/1655  cm−1 (noted as  A1659/A1655) for the fibrillary β-sheet structures. Origin 9.1 software was used for 
the ratio calculation and graphical representation.
Immunohistochemistry. Consecutive 4 µm slices of the tissue samples were embedded in paraffin used 
for the µFTIR analyses were cut and placed in polyLys treated glass slides. Samples were de-waxed by submerg-
ing the samples on xylene (3 × 8 min) and samples were hydrate in 100%, 95%, and 75% ethanol for 2 × 4 min 
each. De-waxed sections were incubated with 98% formic acid (3 min) and samples were boiled in citrate buffer 
(20 min) to enhance antigenicity. Then, the endogenous peroxidases were blocked with Peroxidase-Blocking 
solution (Dako, Denmark) (15 min) and then incubated at 4 °C overnight with the primary antibodies against 
β-amyloid (Clone 6F/3D)(Dako). Sections were subsequently rinsed and incubated with biotinylated goat anti-
mouse and rabbit secondary antibody (Dako), followed by EnVision + System Peroxidase (Dako) and finally 
with the chromogen diaminobenzidine and  H2O2. Sections were lightly counterstained with hematoxylin. After 
staining, the sections were dehydrated and cover-slipped for microscopic  observation17.
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